Open AccessRandomized, Controlled Trial of Budesonide and Prednisone for the Treatment of Idiopathic Inflammatory Bowel Disease in Dogs
Author(s) -
Dye T.L.,
Diehl K.J.,
Wheeler S.L.,
Westfall D.S.
Publication year - 2013
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.12195
Subject(s) - medicine , budesonide , prednisone , adverse effect , gastroenterology , inflammatory bowel disease , randomized controlled trial , incidence (geometry) , corticosteroid , clinical trial , disease , physics , optics
Background Budesonide has been used to treat inflammatory bowel disease ( IBD ) in dogs, but no controlled studies have been performed to evaluate efficacy of this treatment. Objective To compare budesonide and prednisone for induction therapy of IBD in dogs by using IBD activity index scores and evaluating frequency and severity of owner‐reported adverse effects. Animals Forty client‐owned dogs with newly diagnosed idiopathic IBD were enrolled between A pril 2001 and J anuary 2004; 34 dogs completed the 6 week study. Methods Double‐blinded, randomized controlled trial. Dogs were randomized to receive either pure powder‐based budesonide (3–7 kg: 1 mg PO q24h, 7.1–15 kg: 2 mg PO q24h, 15.1–30 kg: 3 mg PO q24h, >30 kg: 5 mg PO q24h) for 6 weeks or prednisone (1 mg/kg PO q12h × 3 weeks then 0.5 mg/kg PO q12h × 3 weeks). IBD activity index ( IBDAI ) scores were determined at diagnosis and after 6 weeks of treatment. Pet owners completed weekly questionnaires regarding clinical signs and incidence and severity of adverse effects. Results Significant differences in remission rates (>75% decrease in IBDAI scores) were not observed with a remission rate of 78% in the budesonide group and 69% in the prednisone group ( P = .70). Frequency of adverse effects was similar between the 2 groups. Conclusions and Clinical Importance There was no demonstrable difference in remission rates or incidence of adverse effects between prednisone and budesonide for induction therapy of IBD in dogs.